Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials ; volume:11 ; number:6 ; day:25 ; month:9 ; year:2024 ; pages:1551-1567 ; date:12.2024
Rheumatology and therapy ; 11, Heft 6 (25.9.2024), 1551-1567, 12.2024
- Urheber
-
Mease, Philip J.
Korotaeva, Tatiana
Shesternya, Pavel
Kokhan, Muza
Rukavitsyn, Anton
Vasilchenkov, Dmitry
Sharaf, Mohamed
Lavie, Frédéric
Deodhar, Atul
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-024-00713-x
- URN
-
urn:nbn:de:101:1-2501292143297.146914681894
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mease, Philip J.
- Korotaeva, Tatiana
- Shesternya, Pavel
- Kokhan, Muza
- Rukavitsyn, Anton
- Vasilchenkov, Dmitry
- Sharaf, Mohamed
- Lavie, Frédéric
- Deodhar, Atul
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis